Table 4.
Indication for FSL-FGM use | Baseline | 6 months | 12 months | Difference (12 months) |
Hypoglycemia unawareness 1 | ||||
Observed | 56.6 (50.0 to 63.0) | 55.0 (49.0 to 62.0) | 55.0 (49.2 to 62.0) | |
Estimated | 57.4 (55.8 to 59.0) | 55.7 (53.6 to 57.9) | 56.9 (54.5 to 59.3) | −0.5 (–4.0 to 3.0) |
Number | 156 | 86 | 73 | |
Unexpected hypoglycemias 2 | ||||
Observed | 58.0 (52.0 to 63.0) | 55.0 (50.0 to 61.0)** | 55.0 (51.0 to 62.0)** | |
Estimated | 58.0 (57.2 to 58.9) | 55.4 (54.3 to 56.5) | 56.2 (55.0 to 57.3) | −1.9 (–1.1 to –0.2) |
Number | 410 | 252 | 218 | |
HbA1c>70 mmol / mol (8.5%) 3 | ||||
Observed | 76.0 (71.0 to 85.0) | 67 (61.0 to 76.8)** | 67.5 (61.0 to 76.0)** | |
Estimated | 79.1 (77.6 to 80.5) | 70.0 (67.9 to 72.0) | 70.4 (68.3 to 72.6) | −8.6 (–11.8 to –5.4) |
Number | 294 | 144 | 132 | |
Unwanted sensation loss of the fingers 4 | ||||
Observed | 66.0 (53.0 to 78.0) | 61.0 (51.0 to 71.8) | 67.5 (58.0 to 73.0)* | |
Estimated | 68.8 (60.0 to 77.5) | 61.6 (49.5 to 73.7) | 65.6 (53.5 to 77.7) | −3.2 (–21.6 to 15.3) |
Number | 19 | 10 | 10 | |
Occupational hazards with hypoglycemia 5 | ||||
Observed | 60.0 (52.5 to 69.0) | 56.0 (49.0 to 62.5)* | 57.4 (49.3 to 65.5) | |
Estimated | 64.0 (60.3 to 67.7) | 58.0 (53.4 to 62.6) | 58.0 (52.7 to 63.3) | −5.9 (–13.9 to 2.0) |
Number | 57 | 37 | 28 | |
Individuals eligible for CGM 6 | ||||
Observed | 59.0 (51.0 to 67.0) | 57.0 (48.5 to 62.0) | 61.0 (51.0 to 65.5) | |
Estimated | 59.1 (55.6 to 62.5) | 57.2 (52.7 to 61.7) | 59.1 (54.2 to 61.1) | 0.1 (–7.3 to 7.5) |
Number | 52 | 43 | 21 | |
Individuals already using FSL-FGM 7 | ||||
Observed | 58.5 (53.3 to 67.0) | 56.0 (51.5 to 62.0) | 56.0 (52.0 to 63.0) | |
Estimated | 60.4 (58.3 to 62.5) | 57.5 (55.0 to 60.1) | 58.2 (55.4 to 60.9) | −2.2 (–6.4 to 2.0) |
Number | 100 | 65 | 39 | |
Multiple indications | ||||
Observed | 63.0 (54.0 to 71.0) | 58.0 (51.0 to 65.0)** | 59.0 (52.0 to 66.0)** | |
Estimated | 63.2 (61.8 to 64.5) | 59.0 (57.2 to 60.7) | 59.5 (57.7 to 61.4) | −3.6 (–6.5 to –0.8) |
Number | 283 | 171 | 146 |
Values are presented as numbers, medians (25th, 75th centiles) and estimated means (difference) (95% CI). Data are presented as observed data and estimated data using the linear mixed model. HbA1c concentrations are presented in mmol/mol.
*p<0.05 as compared with baseline; **p<0.001 as compared with baseline. Detailing of indications: see text and Table.
CGM, continuous glucose monitoring; FSL-FGM, FreeStyle Libre flash glucose monitoring.